Platelet To Lymphocyte Ratio Relationship With Neoadjuvant Chemotherapy Of Caf Regiment Response In Locally Advanced Breast Cancer Patients

Background: Chemotherapy in breast cancer can be given as neoadjuvant or adjuvant therapy. The responseto neoadjuvant chemotherapy is very important in cancer management, especially in locally advanced breastcancer, therefore predictive factors which can predict chemotherapy response are very important. Platelet tolymphocyte ratio is a simple examination, which has been used as predictive factor in various cancer. Thisstudy will be focussing on locally advanced breast cancer.Method: The study design is prospective cohort study. The research subjects examined the levels of plateletsand lymphocytes in the blood before chemotherapy. Blood was drawn 1 day before the first chemotherapysession. Then the patient’s clinical response was assessed after 3 cycles of chemotherapy. Each cycle iscarried out at intervals of 3 weeks. Furthermore, the platelet to lymphocyte ratio and chemotherapy responsewill be assessed and analyzed.Results: The research subjects consisted of 35 women. In this study, it was found that the mean value ofplatelets was 388,228 ± 141.5 g / dl, with a maximum value of 834,000 g / dl and a minimum of 206,000 g /dl. In the lymphocyte, the mean results were 2,025 ± 759 mg / l with a maximum lymphocyte value of 4,210g / dl and a minimum of 800 g / dl. From the results of this study, the mean platelet / lymphocyte ratio was232.9 ± 212.9 uL with a minimum value of 80.51 uL and a maximum of 1052 uL. In this study, it was foundthat most of the patients experienced a partial response in 23 patients (65.7%) and it was found that there wasa significant relationship between the platelet / lymphocyte ratio and the clinical response of local advancedbreast cancer patients with p value = 0.028 (p. <0.05)Conclusion: There is significant relationship between the platelet / lymphocyte ratio and the clinicalresponse of chemotherapy in locally advanced breast cancer patients. The higher the platelet to lymphocyteratio, worse chemotherapy response is expected.